ストックスクリーナーアプリを入手
16.96
0.95%
0.16
プレマーケット:
17.30
0.34
+2.00%
Neuropace Inc (NPCE) 最新ニュース
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st
Financial Review: Vicarious Surgical (NYSE:RBOT) vs. NeuroPace (NASDAQ:NPCE) - Defense World
How NeuroPace Inc. stock performs in rate cut cyclesJuly 2025 Breakouts & Risk Managed Investment Strategies - ulpravda.ru
How resilient is NeuroPace Inc. stock in market downturns2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
Will NeuroPace Inc. stock benefit from green energy trendsWatch List & High Conviction Investment Ideas - ulpravda.ru
Why NeuroPace Inc. stock remains undervaluedGlobal Market Influence & Low Risk Capital Appreciation - ulpravda.ru
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
NeuroPace stock dips after pricing $65M share offering - MSN
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com
Neuropace, Inc. (NPCE) Stock Analysis: Uncovering an 18.90% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Published on: 2025-12-25 19:47:27 - moha.gov.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World
Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда
Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда
Can NeuroPace Inc. stock deliver sustainable ROEWatch List & Fast Entry and Exit Trade Plans - Улправда
Is NeuroPace Inc. stock oversold or undervaluedTrade Exit Report & Expert Curated Trade Ideas - DonanımHaber
Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Aug Rallies: Can NeuroPace Inc. stock deliver sustainable ROETrade Performance Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Lake Street Keeps Their Buy Rating on NeuroPace (NPCE) - The Globe and Mail
UBS Group Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - Defense World
NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment - Investing.com Nigeria
Is It Time To Consider Buying NeuroPace, Inc. (NASDAQ:NPCE)? - Yahoo Finance
NeuroPace Files FDA Application to Expand RNS System Use - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Investing News Network
Neuropace files PMA supplement to FDA - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS - Business Wire
UBS Maintains NeuroPace (NPCE) Buy Recommendation - Nasdaq
UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating - marketscreener.com
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00 - MarketBeat
Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00 at JPMorgan Chase & Co. - Defense World
NeuroPace price target raised to $20 from $18 at JPMorgan - MSN
Bank Watch: How buybacks impact NeuroPace Inc stock value2025 Biggest Moves & AI Forecast Swing Trade Picks - moha.gov.vn
JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com Australia
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - MSN
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy By Investing.com - Investing.com South Africa
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace
Neuropace shows 77% reduction in seizures - BioWorld MedTech
NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com
NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada
Neuropace announces positive 18-month NAUTILUS trial results in idiopathic generalized epilepsy - marketscreener.com
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
2.10%
0.57%
大文字化:
|
ボリューム (24 時間):